Moringa oleifera
Phase 3Small molecule
Moringa oleifera is one of 20 small molecule programs targeting Postpartum Depression. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
21 competitors in Postpartum Depression
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Zoloft
VViatris Specialty LLC
Approved
Spravato
WWim Janssens
Approved
Ketalar
AAultman Health Foundation
Approved
Prometrium
FerringApproved
Ultram
WWim Janssens
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Zulresso
PPresage Biosciences
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis1 trial
Moringa Oleifera1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moringa oleifera. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversitas Sebelas Maret